Diabetes Mine, January 9, 2012: We were familiar with the company ViaCyte through its former identity as NovoCell, when we reported that they’d managed to successfully control diabetes in mice using embryonic stem cells back in 2008. Last year, they changed their name, but their two-part mission remained the same: first, to create fully functioning beta cells (the specific kind of islet cells that make insulin and amylin) from embryonic stem cells, and then to find a way to combat the process that causes the body to attack its own insulin-producing cells.  Read entire article »